Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by georges44on Mar 06, 2008 11:04am
118 Views
Post# 14607054

RE: georges44

RE: georges44
 You can find this information on SEDAR, Prometic document, mar. 28 2007,
Audired Annuel Financial Statements : note 12, page 50:

Note 12. Long-term debt

Current portion 2006 2005

Loan with a nominal value of US$10,000,000,

guaranteed by all assets of the Company, bearing

interest at 15.034 %, payable with monthly instalments

of US$433,250 starting in June 2007. Maturing in

August 2009. (a) $2,630 $11,512 $ –

Loan secured by the Company and a first mortgage

on the capital assets financed by such loan,

bearing interest at 9.5%, payable with monthly

instalments of $7, maturing in June 2007 43 43 412

Obligations under capital leases payable in

monthly instalments of $1, maturing in December 2008

and December 2010 5 22

2,678 11,577 412

Current portion of long term debt 2,678 366

$8,899 $ 46

The instalments on the long-term debt for the next years are as follows:

Year ending December 31:

2007 $ 2,678

2008 5,068

2009 3,825

2010 6

(a) 5,000,855 warrants with an exercise price of $0.3133 per share were issued to the lender as compensation for making

the loan commitment. If in September 2007, the fair market value of the Company’s subordinate voting shares are less than

four (4) times the value of the exercise price, the Company shall be required to compensate the lender with a payment of

US$ 1,400,000 which will be offset by the obligation by the lender to exercise its 5,000,855 warrants, at the agreed-to

exercise price.

Furthermore, 1,786,187 warrants with an exercise price of $0.324 were issued as compensation warrants to the

Company’s agent.

The fair value of the warrants was determined using the Black-Scholes options-pricing model with the following assumptions:

Expected dividend yield of 0%, expected volatility of 70%-80% and 82%, risk-free interest rates of 3.96% and 4.12% and

expected life of three and five years. The estimated fair values of the warrants at the date of grant were respectively $0.298

and $0.24. The total value of the warrants of $1,919 is accounted as deferred financing expenses. Considering the

warrants and other expenses incurred for the long-term debt, the effective interest rate is 32.75%.

Bullboard Posts